002390.KO Handok
- Market cap
- KRW 107B
- P/E
- -
- P/B
- 0.42x
- ROE
- -16.8%
- Dividend yield
- 2.58%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 002390.KO undervalued?
Graham numberThe Graham number of Handok cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Handok fundamental analysis
No fundamental analysis for Handok yet.
Handok stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Handok
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition pr…
Full company profileHandok financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Handok annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 396B | 418B | 447B | 473B | 504B | 518B | 544B | 523B | 507B | 535B | 552B |
| Gross Profit | 128B | 133B | 158B | 166B | 168B | 168B | 174B | 166B | 157B | 159B | 165B |
| Operating Income | 3.64B | -1.87B | 22.1B | 27.5B | 28.4B | 28.0B | 28.5B | 12.6B | 539M | 3.29B | 7.06B |
| EBITDA | - | 30.0B | 35.1B | 76.7B | 70.3B | 31.9B | 37.3B | 2.76B | -20.8B | 35.5B | -7.00B |
| Net Income | -6.45B | 4.87B | 7.99B | 34.9B | 27.0B | 3.29B | 10.7B | -28.8B | -52.6B | -2.15B | -42.5B |
| EPS | - | 391 | 587 | 2,538 | 1,959 | 239 | 776 | -2,092 | -3,819 | -166 | -3,274 |
| Balance Sheet | |||||||||||
| Total Assets | 623B | 639B | 653B | 749B | 819B | 842B | 871B | 790B | 789B | 791B | 780B |
| Total Liabilities | 334B | 349B | 339B | 405B | 437B | 458B | 489B | 450B | 499B | 512B | 525B |
| Shareholders' Equity | 281B | 284B | 307B | 341B | 381B | 384B | 380B | 339B | 287B | 277B | 253B |
| Cash & Short-term Investments | 11.9B | 34.8B | 32.5B | 18.0B | 23.7B | 30.4B | 36.8B | 16.6B | 53.0B | 25.1B | 23.3B |
| Cash Flow | |||||||||||
| Operating Cash Flow | -8.50B | 6.79B | 29.5B | 8.80B | 24.3B | 37.2B | 30.5B | 36.0B | -2.79B | 3.98B | 19.6B |
| Capital Expenditure | 31.7B | 29.2B | 15.8B | 22.0B | 20.4B | 43.0B | 36.2B | 26.2B | 19.4B | 15.8B | 11.7B |
| Free Cash Flow | - | -34.0B | 7.86B | -17.2B | 1.67B | -6.23B | -13.2B | 9.80B | -22.2B | -11.9B | 7.97B |
| Ratios | |||||||||||
| ROE | -2.3% | 1.7% | 2.6% | 10.3% | 7.1% | 0.9% | 2.8% | -8.5% | -18.3% | -0.8% | -16.8% |
| ROA | -1.0% | 0.8% | 1.2% | 4.7% | 3.3% | 0.4% | 1.2% | -3.6% | -6.7% | -0.3% | -5.5% |
| Net Profit Margin | -1.6% | 1.2% | 1.8% | 7.4% | 5.4% | 0.6% | 2.0% | -5.5% | -10.4% | -0.4% | -7.7% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Handok dividends
- Dividend yield
- 2.58%
- Forward dividend
- 200.00 KRW
- Payout ratio
- -
- Ex-dividend date
- Feb 26, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 2.75B | 212 | - |
| 2024 | KRW 4.13B | 300 | - |
| 2023 | KRW 5.51B | 400 | - |
| 2022 | KRW 4.82B | 350 | 45.1% |
| 2021 | KRW 4.13B | 300 | 125.3% |
| 2020 | KRW 3.78B | 275 | 14.0% |
| 2019 | KRW 6.13B | 445 | 17.5% |
| 2018 | KRW 3.30B | 242 | 41.3% |
| 2017 | KRW 1.56B | 125 | 32.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 10:1 on May 2, 2003.
Who owns Handok
- Insiders 42.23%
- Institutions 0.36%
- Public & others 57.42%
- Shares outstanding 13.0M
- Free float 7.18M
Handok company profile
- Company name
- Handok
- Ticker
- 002390.KO
- ISIN
- KR7002390003
- Exchange
- Korea Stock Exchange
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 908
- Fiscal year end
- December
- Address
- 132 Teheran-ro, Seoul, South Korea, 06235
- Phone
- 82 2 527 5114
- Website
- handok.co.kr
About Handok
HANDOK Inc. operates as a pharmaceutical company. The company provides prescription and OTC drugs; medical devices, such as blood pressure monitors, cholesterol monitoring systems, insulin pumps, self-monitoring system of blood glucose, and blood glucose monitoring system; in vitro diagnostic medical devices; as well as life science products. It also offers healthcare products comprising food supplements under the NatureSet brand; food and beverages; and medical nutrition products. In addition, the company engages in real estate leasing. The company was formerly known as Handok Pharmaceuticals Co., Ltd and changed its name to Handok Inc. in July 2013. Handok Inc. was founded in 1954 and is headquartered in Seoul, South Korea.
Handok management
4- Mr. Young-Jin Kim M.B.A.Chairman & CEO · born 1956
- Ms. Jeong-yol ChoPresident
- Ms. Miyeon KimPresident, Director & COO
- Jin Ki BaekVice President & Executive Director